Prosecution Insights
Last updated: November 10, 2026
Application No. 16/652,768

BI-LAYER PHARMACEUTICAL TABLET FORMULATION

Non-Final OA §112
Filed
Apr 01, 2020
Priority
Oct 13, 2017 — provisional 62/571,863 +2 more
Examiner
LOVE, TREVOR M
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VIIV HEALTHCARE COMPANY
OA Round
10 (Non-Final)
44%
Grant Probability
Moderate
10-11
OA Rounds
0m
Est. Remaining
70%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
317 granted / 729 resolved
-16.5% vs TC avg
Strong +27% interview lift
Without
With
+26.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
46 currently pending
Career history
761
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
52.8%
+12.8% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
15.1%
-24.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 729 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 08/12/2026 has been entered. Claims 28-39 are pending and are currently under consideration. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 28 and 29 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted elements are: the amount of purified water. By including “purified water” in a chart that has a column for “range of quantity wt/wt%” or “quantity wt/wt%”, there is implied that there is a specific amount, however, by leaving the space blank, it is unclear if the claim is intending to claim any amount of water, or if the water is present in an amount of q.s. Claim 32 depends from claim 28 without resolving the identified 112 issue, and therefore, suffers from the same deficiency. Claim Objections Claims 28-39 (all claims currently under consideration) are objected to because of the following informalities: Claims 28-31 and 34-37 are objected to because the claims fail to each end in a period. MPEP 608.01(m) expressly states that “Each claim begins with a capital letter and ends with a period.” Appropriate correction is required. Claims 32, 33, 38, and 39 depend from objected to claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to TREVOR M LOVE whose telephone number is (571)270-5259. The examiner can normally be reached M-F typically 6:30-3. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 5712726175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TREVOR LOVE/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Show 26 earlier events
Aug 25, 2025
Response Filed
Nov 07, 2025
Final Rejection mailed — §112
Jan 07, 2026
Response after Non-Final Action
Apr 23, 2026
Request for Continued Examination
Apr 24, 2026
Response after Non-Final Action
Aug 12, 2026
Request for Continued Examination
Aug 13, 2026
Response after Non-Final Action
Aug 25, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778124
A SYNERGISTIC PLANT GROWTH STIMULANT COMPOSITION COMPRISING MELATONIN AND NITROGENOUS COMPOUNDS FOR IMPROVING PLANT GROWTH AND DECREASING BIOTIC-ABIOTIC STRESSES ON PLANTS
3y 1m to grant Granted Nov 03, 2026
Patent 12778130
WATER CONDITIONERS FOR AGRICULTURAL FORMULATIONS
2y 11m to grant Granted Nov 03, 2026
Patent 12772975
INSECT REPELLENT-POLYMER GELS
2y 3m to grant Granted Oct 27, 2026
Patent 12740582
EXTRACTS FOR HEALTH SUPPLEMENTS
3y 6m to grant Granted Sep 22, 2026
Patent 12742182
CYTOKINE IMMUNOTHERAPY
2y 1m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

10-11
Expected OA Rounds
44%
Grant Probability
70%
With Interview (+26.6%)
3y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 729 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month